Patent intelligence · US
US 7662820
Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon
Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon
Patent details — US 7662820
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 16, 2010
- Expiration
- Feb 11, 2030
- Applicant
- SanRx Pharmaceuticals, Inc.
- Claims
- 3
- CPC classes
- A61P, A61P31/00, A61P35/00, A61P37/00
Quick answer
US 7662820 (Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon) is held by SanRx Pharmaceuticals, Inc.. Status: granted. Granted Feb 16, 2010. Expires Feb 11, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SanRx Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61P, A61P31/00, A61P35/00, A61P37/00
Frequently asked questions
What is US patent 7662820?
US 7662820 (Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon) is held by SanRx Pharmaceuticals, Inc.. Status: granted. Granted Feb 16, 2010. Expires Feb 11, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7662820?
SanRx Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 7662820 expire?
Our index shows an expiration date of Feb 11, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.